Skip to main content
. 2011 Jun 15;11(12):1046–1058. doi: 10.4161/cbt.11.12.15709

Figure 2.

Figure 2

Troglitazone decreases c-Myc protein expression in human prostate cancer cells. (A) C4-2 cells were treated with DMSO vehicle or troglitazone 45 εM for indicated times. Following treatment, cells were harvested and the amount of c-Myc and actin protein in each sample was determined using protein gel blot analysis. (B) C4-2 cells were treated with DMSO vehicle or troglitazone (7.5–45 εM) for 48 h. The amount of c-Myc and actin protein in each sample was determined using protein gel blot analysis. (C) PC-3 or LNCaP cells were treated with DMSO vehicle or troglitazone 45 εM for indicated times. Protein gel blot analysis was then used to determine the level of c-Myc and actin protein in each sample.